Genmab A/S GMAB
Set alert
55.29 USD +0.37 +0.67%
As of Nov 3, 12:40 PM ET
55.23 Day range 56.50
23.85 52-week range 57.29
- YTD
- +79.50%
- 1 year
- +92.57%
- Open
- 55.45
- Prev close
- 54.92
- Mkt cap
- 34.00B
- Vol
- 1.67M
- Avg vol
- 3.99M
- EPS
- 1.27
- P/E
- 43.54
- Div yield
- 0.00%
More statistics
- Low
- 55.23
- High
- 56.50
- Forward P/E
- 34.76
- Beta
- 0.55
- Short ratio
- 1.67
- Inst. own
- 20.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 37.12
- 200-d avg
- 30.50
- 1y target
- 64.65
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 64.65 +16.9% upside
Now 55.29
- Target (low)
- 48.00
- Target (mean)
- 64.65
- Target (high)
- 80.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy1
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 11
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.32312 | 0.24 – 0.37 | 0.646 | -50.0% | 8.06B | +21.9% | 6 |
| Next quarter | 0.2566 | 0.17 – 0.32 | 0.047 | +446.0% | 8.60B | +28.6% | 6 |
| Current year | 1.17 | 1.17 – 1.17 | 1.77 | -34.0% | 30.15B | +28.3% | 1 |
| Next year | 1.58 | 1.58 – 1.58 | 1.17 | +35.0% | 36.28B | +20.4% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 29, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Oct 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 26, 2026 | JP Morgan | Upgrade | Neutral | Overweight |
| Oct 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Oct 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 14, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 22, 2026 | TD Cowen | Upgrade | Hold | Buy |
| Jul 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 23, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 27, 2026 | Wolfe Research | Initiated | — | Outperform |
| Mar 2, 2026 | Wells Fargo | Initiated | — | Overweight |
| Feb 23, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 18, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 28, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 7, 2025 | Truist Securities | Reiterated | Buy | Buy |
| Oct 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 24, 2025 | Guggenheim | Upgrade | Neutral | Buy |
| Sep 23, 2025 | Guggenheim | Upgrade | Neutral | Buy |
| Aug 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 8, 2025 | Truist Securities | Maintained | Buy | Buy |